A Dose of Pharma and Biotech News: June 28, 2017

BioAgilytix’s team is committed to keeping on the pulse of bioanalytical innovation in the pharmaceutical and biotechnology industries, and sharing these insights with you, our valued colleagues and customers. Here are some of the headlines we’ve been most interested in recently: Blood Biomarker Signals Huntington’s Disease Bioanalysis Zone, June 7, 2017 Researchers from University College […]

Supreme Court Decision Creates an Opportunity for Biosimilar Developers

The US Supreme Court reached a ruling last week that will allow biosimilar companies to launch new biosimilar drugs more quickly. The decision was unanimous that these companies will not need to provide the reference product sponsor with six months’ notice after US Food and Drug Administration (FDA) approval of their intention to launch a […]

Leading the Way in Large Molecule Bioanalysis, Our Way

BioAgilytix illustrated scientists on globe - Leading the Way in Large Molecule Bioanalysis, Our Way

What makes BioAgilytix a different kind of bioanalytical CRO? It’s all in the way we do large molecule bioanalysis, and how we work together with pharmaceutical and biotechnology companies to accelerate the development of innovative biotherapeutics that can change and save patients’ lives. As you can see, our approach overcomes the common challenges that customers […]